Who are rhG-CSF+rhGM-CSF group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): G-CSF+EPO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rhg-csf-rhgm-csf-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

rhG-CSF+rhGM-CSF group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rhG-CSF+rhGM-CSF group (rhG-CSF+rhGM-CSF group) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hematopoietic growth factor combination. Area: Oncology; Hematology.

marketed Hematopoietic growth factor combination G-CSF receptor; GM-CSF receptor Oncology; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

rhG-CSF+rhGM-CSF group (rhG-CSF+rhGM-CSF group) — Xiamen Amoytop Biotech Co., Ltd.. This combination of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) stimulates the production and activation of neutrophils and myeloid cells to enhance immune function and hematopoietic recovery.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rhG-CSF+rhGM-CSF group TARGET	rhG-CSF+rhGM-CSF group	Xiamen Amoytop Biotech Co., Ltd.	marketed	Hematopoietic growth factor combination	G-CSF receptor; GM-CSF receptor
G-CSF+EPO	G-CSF+EPO	Institute of Liver and Biliary Sciences, India	phase 3	Hematopoietic growth factor combination	G-CSF receptor (GCSFR) and Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hematopoietic growth factor combination class)

Institute of Liver and Biliary Sciences, India · 1 drug in this class
Xiamen Amoytop Biotech Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rhG-CSF+rhGM-CSF group — Competitive Intelligence Brief. https://druglandscape.com/ci/rhg-csf-rhgm-csf-group. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab